- Home
- LVLU vs RPTX Comparison
LVLU vs RPTX Comparison
Compare LVLU & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- RPTX
- Stock Information
- Founded
- LVLU 1996
- RPTX 2016
- Country
- LVLU United States
- RPTX Canada
- Employees
- LVLU N/A
- RPTX N/A
- Industry
- LVLU Catalog/Specialty Distribution
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- RPTX Health Care
- Exchange
- LVLU Nasdaq
- RPTX Nasdaq
- Market Cap
- LVLU 47.5M
- RPTX 54.4M
- IPO Year
- LVLU 2021
- RPTX 2020
- Fundamental
- Price
- LVLU $0.94
- RPTX $1.18
- Analyst Decision
- LVLU Hold
- RPTX Strong Buy
- Analyst Count
- LVLU 3
- RPTX 3
- Target Price
- LVLU $1.58
- RPTX $7.00
- AVG Volume (30 Days)
- LVLU 30.8K
- RPTX 409.8K
- Earning Date
- LVLU 03-05-2025
- RPTX 02-26-2025
- Dividend Yield
- LVLU N/A
- RPTX N/A
- EPS Growth
- LVLU N/A
- RPTX N/A
- EPS
- LVLU N/A
- RPTX N/A
- Revenue
- LVLU $324,699,000.00
- RPTX $66,524,000.00
- Revenue This Year
- LVLU N/A
- RPTX $11.80
- Revenue Next Year
- LVLU $1.72
- RPTX N/A
- P/E Ratio
- LVLU N/A
- RPTX N/A
- Revenue Growth
- LVLU N/A
- RPTX 18.19
- 52 Week Low
- LVLU $0.81
- RPTX $1.10
- 52 Week High
- LVLU $2.13
- RPTX $8.49
- Technical
- Relative Strength Index (RSI)
- LVLU 32.48
- RPTX 35.97
- Support Level
- LVLU $0.82
- RPTX $1.10
- Resistance Level
- LVLU $0.93
- RPTX $1.27
- Average True Range (ATR)
- LVLU 0.07
- RPTX 0.07
- MACD
- LVLU -0.00
- RPTX 0.05
- Stochastic Oscillator
- LVLU 16.60
- RPTX 46.15
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.